

Supplementary Materials: Oncogenic Signalling of PEAK2 Pseudokinase in Colon Cancer

Céline Lecointre, Elise Fourgous, Ingrid Montarras, Clément Kerneur, Valérie Simon, Yvan Boublik, Débora Bonenfant, Bruno Robert, Pierre Martineau and Serge Roche





Figure S1. effect of siRNAs targeting PEAK2 expression colonies formation in the Lovo CRC cells in soft agar. A. relative PEAK2 transcript level in cells transfected with indicated siRNA. B. Anchorage-independent growth in soft agar of CRC cells transfected with indicated siRNA. Is shown mean \pm SEM; n = 3; *p < 0.05; **p < 0.01; ***p < 0.001 (Student's *t* test).

A



B





Figure S2. PEAK2 depletion does not affect RTK or Notch signaling in CRC cells. Is shown MAPK, AKT, Src, Notch and AMPK activities in CRC cells depleted or not PEAK2.

A



B




Figure S3. string analysis of PEAK2 phospho-proteomic (A) and interactomic analysis (50 main hits) (B). This analysis reveals regulators of F-actin assembly as important components of PEAK2 phospho-signaling.




Figure S4. PEAK2 co-localizes with F-actin structures at focal adhesion of transformed cells. Immunostaining of PEAK2^{Myc} and F-actin in SW620 and SrcYFNIH3T3.




Figure S5. Fibronectin induces Y413-dependent PEAK2 phospho-tyrosine signaling. Protein tyrosine phosphorylation induced by indicated PEAK2 mutants transiently transfected in HEK293T cells that were coated or not with fibronectin (FN).

Figure 1A




Figure 1B




Figure 2




Figure 4A




Figure 4C




Figure 5C




Figure 5D




Figure 6A




Figure 6B




Figure 6C




Figure S2A




Figure S2B




Figure S5




Figure S6. original blots used in this study.